专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060078623A1 Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent 审中-公开
标题翻译：含有递送剂的微粒或纳米颗粒的药物制剂
公开(公告)号：US20060078623A1
公开(公告)日：2006-04-13
申请号：US11204778
申请日：2005-08-15
申请人： Nikhil Dhoot , Halina Levchik , Shingai Majuru , George Klein , Jamila Harris , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nai Wang
发明人： Nikhil Dhoot , Halina Levchik , Shingai Majuru , George Klein , Jamila Harris , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nai Wang
IPC分类号： A61K9/50 , A61K9/16 , A61K9/14
CPC分类号： A61K47/12 , A61K9/145 , A61K9/1617 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/4858 , A61K38/28
摘要： This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.
摘要翻译：本发明涉及含有递送剂和/或活性剂的微粒和/或纳米颗粒。本发明还涉及药物制剂和固体剂型，包括活性剂的控释固体剂型和递送剂。

2. 发明申请

US20100055194A1 PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT 审中-公开
标题翻译：包含递送剂的微量元素或纳米颗粒的药物制剂
公开(公告)号：US20100055194A1
公开(公告)日：2010-03-04
申请号：US12550281
申请日：2009-08-28
申请人： Shingai Majuru , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nikhil Dhoot , Halina Levchik , George Klein , Jamila Harris , Nai Fang Wang
发明人： Shingai Majuru , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nikhil Dhoot , Halina Levchik , George Klein , Jamila Harris , Nai Fang Wang
IPC分类号： A61K9/14
CPC分类号： A61K47/12 , A61K9/145 , A61K9/1617 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/4858 , A61K38/28
摘要： This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.
摘要翻译：本发明涉及含有递送剂和/或活性剂的微粒和/或纳米颗粒。本发明还涉及药物制剂和固体剂型，包括活性剂的控释固体剂型和递送剂。

3. 发明申请

US20120189666A1 PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT 审中-公开
标题翻译：包含递送剂的微量元素或纳米颗粒的药物制剂
公开(公告)号：US20120189666A1
公开(公告)日：2012-07-26
申请号：US13303756
申请日：2011-11-23
申请人： Nikhil Dhoot , Halina Levchik , Shingai Majuru , George Klein , Jamila Harris , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nai Fang Wang
发明人： Nikhil Dhoot , Halina Levchik , Shingai Majuru , George Klein , Jamila Harris , Puchun Liu , Steven Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nai Fang Wang
IPC分类号： A61K9/00 , A61P19/08 , A61K38/23 , A61K47/38 , A61K47/12 , A61K31/727
CPC分类号： A61K47/12 , A61K9/145 , A61K9/1617 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/4858 , A61K38/28
摘要： This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.
摘要翻译：本发明涉及含有递送剂和/或活性剂的微粒和/或纳米颗粒。本发明还涉及药物制剂和固体剂型，包括活性剂的控释固体剂型和递送剂。

4. 发明申请

US20060078622A1 Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent 审中-公开
公开(公告)号：US20060078622A1
公开(公告)日：2006-04-13
申请号：US11204756
申请日：2005-08-15
申请人： Shingai Majuru , Puchun Liu , Steve Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nikhil Dhoot , Halina Levchik , George Klcin , Jamila Harris , Nai Wang
发明人： Shingai Majuru , Puchun Liu , Steve Dinh , Jun Liao , Jongbin Lee , Ehud Arbit , Nikhil Dhoot , Halina Levchik , George Klcin , Jamila Harris , Nai Wang
IPC分类号： A61K9/14
CPC分类号： A61K47/12 , A61K9/145 , A61K9/1617 , A61K9/2013 , A61K9/2027 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/4858 , A61K38/28
摘要： This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.

5. 发明申请

US20090209635A1 TOPICAL CROMOLYN FORMULATIONS 有权
标题翻译：主题CROMOLYN制剂
公开(公告)号：US20090209635A1
公开(公告)日：2009-08-20
申请号：US11569285
申请日：2005-05-19
申请人： Puchun Liu , Steven Dinh , Ehud Arbit , Michael M. Goldberg
发明人： Puchun Liu , Steven Dinh , Ehud Arbit , Michael M. Goldberg
IPC分类号： A61K31/352
CPC分类号： A61K31/609 , A61K9/0014 , A61K9/06 , A61K47/10 , A61K47/183
摘要： The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.
摘要翻译：本发明提供一种局部组合物，其包含（a）至少一种递送剂化合物和（b）色甘酸化合物。还提供了治疗方法和制备局部组合物的方法。

6. 发明授权

US09498487B2 Topical cromolyn formulations 有权
标题翻译：局部色甘酸配方
公开(公告)号：US09498487B2
公开(公告)日：2016-11-22
申请号：US11569285
申请日：2005-05-19
申请人： Puchun Liu , Steven Dinh , Ehud Arbit , Michael M. Goldberg
发明人： Puchun Liu , Steven Dinh , Ehud Arbit , Michael M. Goldberg
IPC分类号： A61K31/352 , A61K31/609 , A61K9/00 , A61K9/06 , A61K47/10 , A61K47/18
CPC分类号： A61K31/609 , A61K9/0014 , A61K9/06 , A61K47/10 , A61K47/183
摘要： The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.
摘要翻译：本发明提供一种局部组合物，其包含（a）至少一种递送剂化合物和（b）色甘酸化合物。还提供了治疗方法和制备局部组合物的方法。

7. 发明授权

US08975227B2 Intraoral dosage forms of glucagon 有权
标题翻译：胰高血糖素的口服剂型
公开(公告)号：US08975227B2
公开(公告)日：2015-03-10
申请号：US11994032
申请日：2006-07-17
申请人： Nai Fang Wang , Puchun Liu , Steven Dinh , Michael M. Goldberg , Ehud Arbit
发明人： Nai Fang Wang , Puchun Liu , Steven Dinh , Michael M. Goldberg , Ehud Arbit
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： A61K38/26 , C07K14/605
摘要： The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
摘要翻译：本发明提供包含至少一种递送剂化合物和胰高血糖素的组合物（例如，药物组合物）。优选地，组合物包含治疗有效量的胰高血糖素和递送剂化合物。本发明的组合物有助于胰高血糖素的递送，并且与不含递送剂化合物的给药相比，其生物利用度增加。

8. 发明申请

US20080207514A1 Intraoral Dosage Forms of Glucagon 有权
标题翻译：胰高血糖素的口服剂量形式
公开(公告)号：US20080207514A1
公开(公告)日：2008-08-28
申请号：US11994032
申请日：2006-07-17
申请人： Nai Fang Wang , Puchun Liu , Steven Dinh , Michael M. Goldberg , Ehud Arbit
发明人： Nai Fang Wang , Puchun Liu , Steven Dinh , Michael M. Goldberg , Ehud Arbit
IPC分类号： A61K38/26 , A61P3/10
CPC分类号： A61K38/26 , C07K14/605
摘要： The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
摘要翻译：本发明提供包含至少一种递送剂化合物和胰高血糖素的组合物（例如药物组合物）。优选地，组合物包含治疗有效量的胰高血糖素和递送剂化合物。本发明的组合物有助于胰高血糖素的递送，并且与不含递送剂化合物的给药相比，其生物利用度增加。

9. 发明授权

US08729016B2 Oral insulin therapies and protocol 有权
标题翻译：口服胰岛素治疗和方案
公开(公告)号：US08729016B2
公开(公告)日：2014-05-20
申请号：US12485521
申请日：2009-06-16
申请人： Ehud Arbit , Michael Goldberg , Shingai Majuru
发明人： Ehud Arbit , Michael Goldberg , Shingai Majuru
IPC分类号： A61K38/28
CPC分类号： A61K38/28 , A61B5/14532 , A61K31/192 , A61K38/00
摘要： Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.
摘要翻译：用于治疗哺乳动物葡萄糖耐量异常和早期和晚期糖尿病的方法，用于预防性保护和细胞功能，有助于预防和细胞死亡，预防2型糖尿病哺乳动物的明显糖尿病发作，治疗目前的包括葡萄糖耐量降低或糖尿病患者的血糖控制功能障碍的水平，包括口服给药胰岛素和促进胰岛素在进食之前或之后的胰岛素从胃肠道吸收的递送剂，例如在摄取前约10分钟内一顿饭，慢性的。除了施用快速作用的胰岛素以提供第一胰岛素峰之外，所述方法还包括施用缓慢作用的胰岛素以提供在稍后时间但持续时间更长的时间发生的第二胰岛素峰。这些方法可以改善血糖控制，没有低血糖，高胰岛素血症和体重增加的风险，以及通常与胰岛素治疗相关的频繁血糖监测的需要。

10. 发明申请

US20080175907A1 ORAL INSULIN THERAPIES AND PROTOCOL 审中-公开
标题翻译：口服胰岛素治疗和协议
公开(公告)号：US20080175907A1
公开(公告)日：2008-07-24
申请号：US12040293
申请日：2008-02-29
申请人： Ehud Arbit , Michael Goldberg , Shingai Majuru
发明人： Ehud Arbit , Michael Goldberg , Shingai Majuru
IPC分类号： A61K9/20 , A61K38/28 , A61P3/10
CPC分类号： A61K38/28 , A61B5/14532 , A61K31/192 , A61K38/00
摘要： Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.
摘要翻译：用于治疗哺乳动物葡萄糖耐量异常和早期和晚期糖尿病的方法，用于预防性节省β-细胞功能，有助于预防β-细胞死亡，预防2型糖尿病哺乳动物的明显糖尿病发作，治疗目前的水平具有葡萄糖耐量降低或糖尿病的哺乳动物的血糖控制功能障碍，包括在摄食之前或之后约10分钟内口服胰岛素和促进胰岛素从胃肠道吸收的输送剂，长期的。除了施用快速作用的胰岛素以提供第一胰岛素峰之外，所述方法还包括施用缓慢作用的胰岛素以提供在稍后时间但持续时间更长的时间发生的第二胰岛素峰。这些方法可以改善血糖控制，没有低血糖，高胰岛素血症和体重增加的风险，以及通常与胰岛素治疗相关的频繁血糖监测的需要。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式